admin
Author: Dr K Aggarwal, President CMAAO, With input from Dr Monica Vasudev
COVID-19 vaccine tracker
- To date, just two coronavirus vaccine has been approved. Sputnik V developed by the Gamaleya Research Institute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August.
- A second vaccine in Russia, EpiVacCorona, has also been granted regulatory approval, also without entering Phase 3 clinical trials.
| AZD1222 | Replication-deficient viral vector vaccine (adenovirus from chimpanzees) | The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India | Phase 3 | The University of Oxford, the Jenner Institute | |
| BNT162 | mRNA-based vaccine | Pfizer, BioNTech | Phase 3 | Multiple study sites in Europe and North America | |
| mRNA-1273 | mRNA-based vaccine | Moderna | Phase 3 | Kaiser Permanente Washington Health Research Institute | |
| Ad5-nCoV | Recombinant vaccine (adenovirus type 5 vector) | CanSino Biologics | Phase 3 | Tongji Hospital; Wuhan, China | |
| CoronaVac | Inactivated vaccine (formalin with alum adjuvant) | Sinovac | Phase 3 | Sinovac Research and Development Co., Ltd. | |
| Covaxin | Inactivated vaccine | Bharat Biotech; National Institute of Virology | Phase 3 | ||
| JNJ-78436735 (formerly Ad26.COV2.S) | Non-replicating viral vector | Johnson & Johnson | Phase 3 | Johnson & Johnson | |
| No name announced | Inactivated vaccine | Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | Phase 3 | Henan Provincial Center for Disease Control and Prevention | |
| NVX-CoV2373 | Nanoparticle vaccine | Novavax | Phase 3 | Novavax | |
| Sputnik V | Non-replicating viral vector | Gamaleya Research Institute, Acellena Contract Drug Research and Development | Phase 3 | Various |
| Bacillus Calmette-Guerin (BCG) vaccine | Live-attenuated vaccine | University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital | Phase 2/3 | University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital | |
| INO-4800 | DNA vaccine (plasmid) | Inovio Pharmaceuticals | Phase 2/3 | Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia | |
| VIR-7831 | Plant-based adjuvant vaccine | Medicago; GSK; Dynavax | Phase 2/3 | Medicago | |
| No name announced | Recombinant vaccine | Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences | Phase 2 | Various | |
| ZyCoV-D | DNA vaccine (plasmid) | Zydus Cadila | Phase 2 | Zydus Cadila | |
| No name announced | Adjuvanted protein subunit vaccine | Phase 1/2 | |||
| AG0301-COVID19 | DNA vaccine | AnGes, Inc. | Phase 1/2 | AnGes, Inc.; Japan Agency for Medical Research and Development | |
| BBIBP-CorV | Inactivated vaccine | Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | Phase 1/2 | Henan Provincial Center for Disease Control and Prevention | |
| EpiVacCorona | Peptide vaccine | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | Phase 1/2 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | |
| GX-19 | DNA vaccine | Genexine | Phase 1/2 |
| LNP-nCoVsaRNA | Self-amplifying RNA vaccine | Imperial College London | Phase 1/2 | Imperial College London | |
| ARCT-021 (LUNAR-COV19) | Self-replicating RNA vaccine | Arcturus Therapeutics and Duke-NUS Medical School | Phase 1/2 | Duke-NUS Medical School, Singapore | |
| No name announced | Protein subunit vaccine | Sanofi; GlaxoSmithKline | Phase 1/2 | Various | |
| No name announced | Inactivated vaccine | Chinese Academy of Medical Sciences, Institute of Medical Biology | Phase 1/2 | West China Second University Hospital, Yunnan Center for Disease Control and Prevention | |
| AdimrSC-2f | Protein subunit vaccine | Adimmune | Phase 1 | Adimmune | |
| bacTRL-Spike | Monovalent oral vaccine (bifidobacteria) | Symvivo | Phase 1 | Symvivo Corporation | |
| COVAX-19 | Monovalent recombinant protein vaccine | Vaxine Pty Ltd. | Phase 1 | Royal Adelaide Hospital | |
| CVnCoV | mRNA-based vaccine | CureVac | Phase 1 | CureVac | |
| DelNS1-2019-nCoV-RBD-OPT1 | Replicating viral vector | Xiamen University, Beijing Wantai Biological Pharmacy | Phase 1 | Jiangsu Provincial Centre For Disease Control and Prevention | |
| GRAd-COV2 | Adenovirus-based vaccine | ReiThera; Leukocare; Univercells | Phase 1 | Lazzaro Spallanzani National Institute for Infectious Diseases |
| UQ-CSL V451 | Protein subunit vaccine | CSL; The University of Queensland | Phase 1 | ||
| No name announced | Adenovirus-based vaccine | ImmunityBio; NantKwest | Phase 1 | ||
| SCB-2019 | Protein subunit vaccine | GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI | Phase 1 | Linear Clinical Research (Australia) | |
| UB-612 | Multitope peptide-based vaccine | COVAXX | Phase 1 | United Biomedical Inc. (UBI) | |
| V590 | Recombinant vaccine (vesicular stomatitis virus) | Merck; IAVI | Phase 1 | ||
| V591 | Measles vector vaccine | University of Pittsburgh’s Center for Vaccine Research | Phase 1 | University of Pittsburgh; Themis Biosciences; Institut Pasteur | |
| VXA-CoV2-1 | Recombinant vaccine (adenovirus type 5 vector) | Vaxart | Phase 1 | Vaxart | |
| AAVCOVID | Gene-based vaccine | Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania | Pre-clinical | ||
| AdCOVID | Intranasal vaccine | Altimmune | Pre-clinical | University of Alabama at Birmingham | |
| ChAd-SARS-CoV-2-S | Adenovirus-based vaccine | Washington University School of Medicine in St. Louis | Pre-clinical | Washington University School of Medicine in St. Louis |
| T-COVIDTM | Intranasal vaccine | Altimmune | Pre-clinical |
HealthySoch
